GlassScriptPhysician profile
Kathleen Flood
NPI 1053021816
$1,511.00
in general payments reported to CMS, 2019-2025
18 companies · $688 in 2025
The $688 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $823 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $482.00 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $147.57 | 2024 | |
| Phathom Pharmaceuticals, INC. | $147.54 | 2024-2025 | Voquezna |
| Abbvie INC. | $124.28 | 2024-2025 | |
| Verona Pharma, INC. | $121.53 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $93.76 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $87.85 | 2024-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $68.68 | 2025 | Rexulti |
| Viatris Specialty LLC | $30.52 | 2025 | Yupelri |
| Philips North America LLC | $30.00 | 2024 | (Ak6) Vest Therapy |
| Glaxosmithkline, LLC. | $26.56 | 2025 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $24.36 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $23.91 | 2024 | Strensiq |
| Medtronic, INC. | $23.71 | 2025 | Intellis Adaptivestim |
| Exact Sciences Corporation | $21.31 | 2025 | The Cologuard Plus Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.86 | 2025 | |
| Becton, Dickinson and Company | $18.80 | 2024 | Phasix Mesh |
| Shield Therapeutics INC | $17.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Flood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.